NMOSD Clinical Trials
Award-winning chef Christine Há, who is blind as a result of her NMOSD, is the public face of a new initiative called “NMOSD Won’t Stop Me.”
NORD and other rare disease organizations around the world will celebrate Rare Disease Day on February 28, 2022, with most events being held virtually.
People of African origin are 2-3 times more likely than Caucasians to develop NMOSD. Evanthia Bernitsas, MD, has spent much of her career trying to understand why.
Neuropathic pain is frequent in NMOSD patients and conventional medications for neuropathic pain management have limited efficacy, a review shows.
The Guthy-Jackson Charitable Foundation and the Siegel Rare Neuroimmune Association are racing to find a cure for neuromyelitis optica spectrum disorder (NMOSD).
Part 1 of 2: Neuromyelitis optica spectrum disorder (NMOSD) columnist Teaira Daniels sets the stage for how rare diseases turned her world upside down.
Columnist Teaira Daniels will provide valuable insights into living and learning from life with neuromyelitis optica spectrum disorder (NMOSD).
NMOSD Clinical Insights
We review current (and future) therapies for neuromyelitis optica spectrum disorder and discuss how the treatment landscape Is changing.
With the updated definition of neuromyelitis optica spectrum disorder in 2015, studies have estimated a rise of around 1.5 fold in disease prevalence.
We compare the most common types of first-line immunosuppressants currently used to treat neuromyelitis optica spectrum disorder (NMOSD).
Researchers are investigating anecdotal reports of NMOSD relapse associated with COVID-19 vaccines and examining the science behind them.
In the management of any disease in which relapses are known to occur, it is important to identify the risk factors for their occurrence, as well as any other factors that might influence their severity. In this article, we will be assessing the risk factors for relapse in patients with neuromyelitis optica spectrum disorder (NMOSD)…
We explore the efficacy and mechanisms of 3 immunosuppressive therapies that have been approved for use in neuromyelitis optica spectrum disorder (NMOSD).
Rare Care Podcast